Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum : Closing results after 5 years of follow-up
✍ Scribed by Christoph P. Schuhmacher; Ulrich Fink; Karen Becker; Raymonde Busch; Hans-Joachim Dittler; James Mueller; J. Rüdiger Siewert
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 133 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
The intent to curatively treat patients with gastric carcinoma is based on complete surgical resection of the primary tumor and its lymphatic drainage. Postoperative adjuvant chemotherapy has failed to show a significant prognostic advantage for these patients. Preoperative chemotherapy, based on promising results in the treatment of patients with disease in primarily unresectable stages, is still being evaluated for those with locally advanced gastric carcinoma. Most published studies still lack adequate staging methods, and long term results of this treatment modality are not known at present.